Izinzuzo zezeMpilo, iziSebenzi, nokunye
I-rose hip isisiqhamo esivela kwiintyatyambo zityalo zasendle zasendle. Isithako esifanayo kwiiyobisi ze-herbal, i-hip rose ibuye ifumaneke kwisongezelelo kunye nefom. I-rose hip iqulethe inani le-antioxidants, kuquka i- vitamin C , i-vitamin E, i-beta-carotene kunye ne- lycopene .
Ukusetyenziswa kweRose Hip
Ngenye iyeza, i-hip iphakanyiswe njengendlela yendalo yokulungisa iindidi zeengxaki zempilo, kuquka:
- arthritis
- umqolo obuhlungu
- iswekile
- gallstones
- gout
- sciatica
- zilonda
- izifo zogcino
Ukongezelela, isisindo sokunyuka sixhomekeke ekuqiniseni isistim somzimba , sishukumise ukujikeleza, sinciphise ukuvutha kwaye sincede ukukhusela isifo senhliziyo .
Izinzuzo zezeMpilo zikaRose Hip
Nangona uphando ngemiphumo yempilo ye-rose hip inqabile, kukho ubungqina bokuba ukunyuka kwe-hip kunokunika izibonelelo ezithile. Nanku ukukhangela kwiziphumo eziphambili zophando:
1) IArthritis
Inani leengcaphephe zibonisa ukuba i-hip hip inganceda ukunyanga i- osteoarthritis kunye ne- rheumatoid arthritis .
Ngophando luka-2005 kwi- Scandinavia Journal of Rheumatology , abaphandi bafumene ukuba i-hip ye-rose ingaba ne-osteoarthritis. Kuhlolisiso, izigulane ezingama-94 ezine-osteoarthritis ze-hip okanye idolo zaziphathwa kunye ne-hip okanye i-placebo kwiinyanga ezintathu. Ekupheleni kokufunda, amalungu eqela le-hip rose afumana ukuhla kwehle kakhulu kwiintlungu kunye nokusetyenziswa kweyeza zentlungu kunezo zeqela le-placebo.
Okwangoku, uphando olwenziwa ngo-2010 kwi- Phytomedicine lufumene ukuba izigulane ze-rheumatoid arthritis zingenelwa ngokudibanisa i-hip powder ekunakekeleni kwabo. Isi sifundo sasiquka izigulane ezingama-89 ze-rheumatoid arthritis, ngasinye sazo siphathwe nge-rosebop supplements okanye indawo ye-placebo ezintandathu. Amalungu eqela le-hip rose aphelela ekuboniseni ukuphuculwa okukhulu kumanyathelo athile okusebenza ngokomzimba, nangona kwakungekho umehluko omkhulu kumanqanaba entlungu phakathi kwamaqela amabini.
2) Izifo zentliziyo
I-rose hip inokunceda ukukhusela isifo senhliziyo kubantu abagqithiseleyo, ngokutsho kwincwadana encinci kwi- European Journal ye-Clinical Nutrition . Kulo cwaningo, abantu abangama-31 abagqithisileyo basebenzisa isiselo esinompu we-hip okanye i-placebo nsuku zonke kwiiveki ezintandathu. Ekupheleni kwesi sifundo, amalungu eqela le-hip rose abonisa ukuphucula okukhulu kwizinto ezinobungozi zesifo senhliziyo (ezifana nesondlo segazi se- systolic kunye ne- cholesterol ephezulu ) xa kuthelekiswa nalabo beqela le-placebo. Nangona kunjalo, ezinye izinto ezinobungozi (ezifana nokunyuka kwengcinezelo yegazi ye-diastolic kunye namazinga akhulayo okuvuvuka) awazange ahluke phakathi kwamaqela amabini.
3) Isifo sikashukela
Uphando oluphambili lubonisa ukuba i-hip hip inganceda ukulwa nesifo sikashukela. Ngophando luka-2011 kwi- American Journal of Physiology: I-Endocrinology kunye ne-Metabolism , izazinzulu ziye zafumanisa ukuba iiveki ezingama-20 zonyango kunye ne-hip rose hip zanceda ukukhuselwa kwesifo sikashukela kwiigundane kwondla ukutya okunamafutha aphezulu. I-rose hip yabonakala kwakhona ekuncedeni ukulawula umlinganiselo weshukela wegazi kwaye ugcine i-cholesterol kwisheke. Nangona kunjalo, kungekudala ukuxelela ukuba i-rose hip ingakwazi ukunceda ukukhusela isifo sikashukela kubantu.
Bona ezinye iziNyango zeNdalo zesifo sikashukela .
Imijelo
Nangona i-hip iphakama ngokuqhelekileyo ithathwa njengekhuselekile, ukuthatha izilwanyana ezinamafutha athile kunye kunye namayeza athile (njengamachiza aqhekeza igazi kunye nama-anti-inflammatory agents) angenza iziphumo eziyingozi.
Kubalulekile ukudibana nodokotela wakho ngaphambi kokusebenzisa izongezelelo ze-hip.
Izibonelelo azange zivavanywe ukhuseleko kwaye ngenxa yokuba izongezo zokutya zikhululekile kakhulu, umxholo weemveliso ezithile zingahluka kwizinto ezichaziweyo kwilebula yomkhiqizo.
Kwakhona ugcine ukhumbule ukuba ukhuseleko lwezongezelelo kwabasetyhini abakhulelweyo, oomama abangabongikazi, abantwana kunye nalabo abanezifo zonyango okanye abo bathabatha imishanguzo ayilwanga. Unokufumana iingcebiso ezongezelelweyo ekusebenziseni izongezo apha .
Ukusebenzisa iRose Hip yezeMpilo
Nangona ngokukhawuleza ukuba ucebise i-hip ye-rose kwiinjongo ezinxulumene nempilo, kunokwenzeka ukuba ukwandisa ukutya kwakho (ngokuphuza ii-teas teas, umzekelo) unokufumana inzuzo kwimpilo yakho.
Ukuba uqwalasela ukusetyenziswa kwezilwanyana ze-rose hip kunyango lwezempilo ethile, xela ugqirha ngaphambi kokuba uqalise i-regimen yokuncedisa. Kubalulekile ukuba uqaphele ukuba ukuzinyamezela imeko engapheliyo kunye ne-hip rose kunye nokuphepha okanye ukulibazisa ukunakekelwa okuqhelekileyo kunokuba nemiphumo emibi.
> Imithombo:
> Andersson U, Berger K, Högberg A, Landin-Olsson M, Holm C. "Iimiphumo ze-Rose Hip Intake kwiMpawu zeMngcipheko yohlobo lwesibini sikashukela kunye neengqondo ze-Cardiovascular Disease: i-Randomized, Double-Blind, Uphando oluPhezulu kubantu abaThile. "I-Eur J Clinical Nutrition. NgoNovemba ka-2011. 14. Ingqwalasela: 10.1038 / ejcn.2011.203.
> Andersson U, Henriksson E, Ström K, Alenfall J, Göransson O, Holm C. "U-Rose Hip Usebenza Ngeempembelelo Zama-Antidiabetic ngeNdlela Echaphazela Ukunciphisa I-Lippenic Hepatic Programme." U-J Physiol Endocrinol Metab. NgoJan 2011; 300 ( > 1): E111-21 >.
> I-Chrubasik C, i-Duke RK, i-Chrubasik S. "Ububungqina bokusebenza kweCliniki ye-Rose Hip kunye neMbewu: uVavanyo oluHlolo." I-Phytother Res. 2006 uJan; 20 (1): 1-3.
> Chrubasik C, Roufogalis BD, uMüller-Ladner U, uChrubasik S. "Ukuphononongwa ngokuSingqinisiso kwiRosa Canina Impumelelo kunye neZiko loLwazi. IRhy res. 2008 Juni; 22 (6): 725-33.
> Willich SN, Rossnagel K, Roll S, Wagner A, Mune O, > Erlendson > J, Kharazmi A, Sörensen H, Winther K. "Rose Hip Herbal Isixazululo kwizigulane nge-Rheumatoid Arthritis. Phytomedicine. 2010 Feb; 17 (2): 87-93.
> Winther K, Apel K, Thamsborg G. "I-Powder eyenziwe ngembewu kunye ne-Shells ze-Subspecies ze-Rose-Hip (uRosa Canina) Iyanciphisa iimpawu ze-Knee ne-Hip Osteoarthritis: I-Randomized, Double-Blind, i-Placebo-Controlled Trial Trial. "I-Scand J Rheumatol. 2005 Julayi-Aug; 34 (4): 302-8.